Use of biosimilars in inflammatory bowel disease : a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)
Copyright © 2019 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved..
The first infliximab biosimilar for the treatment of inflammatory bowel disease (IBD) was introduced in 2013, and today eight anti-TNF alpha biosimilars (three for infliximab and five for adalimumab) have been approved and licensed by the European Medicines Agency. Biosimilars present great potential in terms of cost saving and possible consequential reinvestment in the health care system. The increasing knowledge about the process of biosimilar development and use in IBD and the publication of many prospective clinical studies and real-life clinical experiences have progressively changed the point of view of IBD physicians. In the present position paper, the Italian Group for the Study of Inflammatory Bowel Disease present and discuss their updated statements and positions on this topic, with emphasis on the concepts of biosimilarity and extrapolation across indications, safety and immunogenicity, interchangeability and switching, automatic substitution, and, finally, patient education about biosimilars.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver - 51(2019), 5 vom: 01. Mai, Seite 632-639 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fiorino, Gionata [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.02.2020 Date Revised 31.10.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.dld.2019.02.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM294951652 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM294951652 | ||
| 003 | DE-627 | ||
| 005 | 20231225082609.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.dld.2019.02.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0983.xml |
| 035 | |a (DE-627)NLM294951652 | ||
| 035 | |a (NLM)30872085 | ||
| 035 | |a (PII)S1590-8658(19)30067-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fiorino, Gionata |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of biosimilars in inflammatory bowel disease |b a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.02.2020 | ||
| 500 | |a Date Revised 31.10.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a The first infliximab biosimilar for the treatment of inflammatory bowel disease (IBD) was introduced in 2013, and today eight anti-TNF alpha biosimilars (three for infliximab and five for adalimumab) have been approved and licensed by the European Medicines Agency. Biosimilars present great potential in terms of cost saving and possible consequential reinvestment in the health care system. The increasing knowledge about the process of biosimilar development and use in IBD and the publication of many prospective clinical studies and real-life clinical experiences have progressively changed the point of view of IBD physicians. In the present position paper, the Italian Group for the Study of Inflammatory Bowel Disease present and discuss their updated statements and positions on this topic, with emphasis on the concepts of biosimilarity and extrapolation across indications, safety and immunogenicity, interchangeability and switching, automatic substitution, and, finally, patient education about biosimilars | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Anti-TNFα | |
| 650 | 4 | |a Biosimilars | |
| 650 | 4 | |a Crohn’s disease | |
| 650 | 4 | |a Inflammatory bowel disease | |
| 650 | 4 | |a Tumor necrosis factor alpha | |
| 650 | 4 | |a Ulcerative colitis | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Biosimilar Pharmaceuticals |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a Infliximab |2 NLM | |
| 650 | 7 | |a B72HH48FLU |2 NLM | |
| 650 | 7 | |a Adalimumab |2 NLM | |
| 650 | 7 | |a FYS6T7F842 |2 NLM | |
| 700 | 1 | |a Caprioli, Flavio |e verfasserin |4 aut | |
| 700 | 1 | |a Daperno, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Mocciaro, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Principi, Mariabeatrice |e verfasserin |4 aut | |
| 700 | 1 | |a Viscido, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Fantini, Massimo Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Orlando, Ambrogio |e verfasserin |4 aut | |
| 700 | 1 | |a Papi, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Annese, Vito |e verfasserin |4 aut | |
| 700 | 1 | |a Danese, Silvio |e verfasserin |4 aut | |
| 700 | 1 | |a Vecchi, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Rizzello, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Armuzzi, Alessandro |e verfasserin |4 aut | |
| 700 | 0 | |a National patients’ association representatives |e verfasserin |4 aut | |
| 700 | 1 | |a Leone, Salvatore |e investigator |4 oth | |
| 700 | 1 | |a Previtali, Enrica |e investigator |4 oth | |
| 700 | 1 | |a Aloi, Marina |e investigator |4 oth | |
| 700 | 1 | |a Alvisi, Patrizia |e investigator |4 oth | |
| 700 | 1 | |a Antonelli, Elisabetta |e investigator |4 oth | |
| 700 | 1 | |a Ardizzone, Sandro |e investigator |4 oth | |
| 700 | 1 | |a Astegiano, Marco |e investigator |4 oth | |
| 700 | 1 | |a Baldoni, Monia |e investigator |4 oth | |
| 700 | 1 | |a Beltrami, Marina |e investigator |4 oth | |
| 700 | 1 | |a Biancone, Livia |e investigator |4 oth | |
| 700 | 1 | |a Bodini, Giorgia |e investigator |4 oth | |
| 700 | 1 | |a Buda, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Bossa, Fabrizio |e investigator |4 oth | |
| 700 | 1 | |a Bracci, Fiammetta |e investigator |4 oth | |
| 700 | 1 | |a Calabrese, Emma |e investigator |4 oth | |
| 700 | 1 | |a Cappello, Maria |e investigator |4 oth | |
| 700 | 1 | |a Castiglione, Fabiana |e investigator |4 oth | |
| 700 | 1 | |a Ciacci, Carolina |e investigator |4 oth | |
| 700 | 1 | |a Cicala, Michele |e investigator |4 oth | |
| 700 | 1 | |a Ciccocioppo, Rachele |e investigator |4 oth | |
| 700 | 1 | |a Comberlato, Michele |e investigator |4 oth | |
| 700 | 1 | |a Cortelezzi, Claudio Camillo |e investigator |4 oth | |
| 700 | 1 | |a Cosintino, Rocco |e investigator |4 oth | |
| 700 | 1 | |a Costa, Francesco |e investigator |4 oth | |
| 700 | 1 | |a Costantino, Giuseppe |e investigator |4 oth | |
| 700 | 1 | |a Cucchiara, Salvatore |e investigator |4 oth | |
| 700 | 1 | |a Cuomo, Antonio |e investigator |4 oth | |
| 700 | 1 | |a D'Incà, Renata |e investigator |4 oth | |
| 700 | 1 | |a Di Paolo, Maria Carla |e investigator |4 oth | |
| 700 | 1 | |a Di Sabatino, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Di Sario, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Frieri, Giuseppe |e investigator |4 oth | |
| 700 | 1 | |a Fries, Walter |e investigator |4 oth | |
| 700 | 1 | |a Gasbarrini, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Geccherle, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Gionchetti, Paolo |e investigator |4 oth | |
| 700 | 1 | |a Graziani, Maria Giovanna |e investigator |4 oth | |
| 700 | 1 | |a Grossi, Laurino |e investigator |4 oth | |
| 700 | 1 | |a Guidi, Luisa |e investigator |4 oth | |
| 700 | 1 | |a Imperiali, Gianni |e investigator |4 oth | |
| 700 | 1 | |a Latella, Giovanni |e investigator |4 oth | |
| 700 | 1 | |a Lionetti, Paolo |e investigator |4 oth | |
| 700 | 1 | |a Inserra, Gaetano |e investigator |4 oth | |
| 700 | 1 | |a Maconi, Giovanni |e investigator |4 oth | |
| 700 | 1 | |a Manguso, Francesco |e investigator |4 oth | |
| 700 | 1 | |a Marino, Marco |e investigator |4 oth | |
| 700 | 1 | |a Mastronardi, Mauro |e investigator |4 oth | |
| 700 | 1 | |a Mazzuoli, Silvia |e investigator |4 oth | |
| 700 | 1 | |a Meucci, Gianmichele |e investigator |4 oth | |
| 700 | 1 | |a Mendolaro, Marco |e investigator |4 oth | |
| 700 | 1 | |a Milla, Monica |e investigator |4 oth | |
| 700 | 1 | |a Mocci, Giammarco |e investigator |4 oth | |
| 700 | 1 | |a Monteleone, Giovanni |e investigator |4 oth | |
| 700 | 1 | |a Bortoluzzi, Francesco Neri |e investigator |4 oth | |
| 700 | 1 | |a Pagnini, Cristiano |e investigator |4 oth | |
| 700 | 1 | |a Pastorelli, Luca |e investigator |4 oth | |
| 700 | 1 | |a Pica, Roberta |e investigator |4 oth | |
| 700 | 1 | |a Piergallini, Simona |e investigator |4 oth | |
| 700 | 1 | |a Privitera, Antonello |e investigator |4 oth | |
| 700 | 1 | |a Renna, Sara |e investigator |4 oth | |
| 700 | 1 | |a Ribaldone, Davide Giuseppe |e investigator |4 oth | |
| 700 | 1 | |a Ricci, Chiara |e investigator |4 oth | |
| 700 | 1 | |a Rispo, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Rocca, Rodolfo |e investigator |4 oth | |
| 700 | 1 | |a Romano, Claudio |e investigator |4 oth | |
| 700 | 1 | |a Romano, Marco |e investigator |4 oth | |
| 700 | 1 | |a Russo, Giovanni |e investigator |4 oth | |
| 700 | 1 | |a Sablich, Renato |e investigator |4 oth | |
| 700 | 1 | |a Saibeni, Simone |e investigator |4 oth | |
| 700 | 1 | |a Savarino, Edoardo |e investigator |4 oth | |
| 700 | 1 | |a Scribano, Maria Lia |e investigator |4 oth | |
| 700 | 1 | |a Spagnuolo, Rocco |e investigator |4 oth | |
| 700 | 1 | |a Stasi, Elisa |e investigator |4 oth | |
| 700 | 1 | |a Terpin, Maria Maddalena |e investigator |4 oth | |
| 700 | 1 | |a Testa, Anna |e investigator |4 oth | |
| 700 | 1 | |a Valpiani, Daniela |e investigator |4 oth | |
| 700 | 1 | |a Variola, Angela |e investigator |4 oth | |
| 700 | 1 | |a Vernia, Piero |e investigator |4 oth | |
| 700 | 1 | |a Vitale, Giovanna |e investigator |4 oth | |
| 700 | 1 | |a Zoli, Giorgio |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver |d 2000 |g 51(2019), 5 vom: 01. Mai, Seite 632-639 |w (DE-627)NLM108968790 |x 1878-3562 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2019 |g number:5 |g day:01 |g month:05 |g pages:632-639 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.dld.2019.02.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2019 |e 5 |b 01 |c 05 |h 632-639 | ||